african
sleep
sick
remain
one
neglect
life
threaten
diseas
left
untreat
till
date
two
form
human
african
trypanosomiasi
hat
identifi
parasit
depend
first
one
trypanosoma
brucei
gambiens
b
gambiens
caus
human
chronic
infect
endem
western
central
africa
trypanosoma
brucei
rhodesiens
b
rhodesiens
vast
anim
reservoir
caus
acut
ill
peopl
eastern
southern
african
countri
hat
high
occur
remot
rural
area
surveil
weak
nonexist
thousand
estim
case
accord
world
health
organ
estim
halfmillion
case
hat
sleep
sick
result
infect
brucei
rhodesiens
brucei
gambiens
attribut
death
annual
diseas
recent
estim
new
case
occur
per
year
million
peopl
risk
six
clinic
approv
drug
treatment
hat
five
suramin
pentamidin
melarsoprol
eflornithin
nifurtimox
discov
year
ago
suramin
pentamidin
ioniz
physiolog
ph
unabl
cross
blood
brain
barrier
therapeut
concentr
thu
use
treatment
hemolymphat
earli
stage
hat
caus
b
rhodesiens
b
gambiens
infect
respect
treatment
second
neurolog
stage
parasit
invad
central
nervou
system
cn
reli
organoarsen
drug
melarsoprol
recent
regist
eflornithin
latter
ineffect
b
rhodesiens
sleep
sick
use
primarili
control
cnsinvolv
hat
caus
b
gambiens
exist
antitrypanosom
therapi
suffer
unaccept
toxic
poor
efficaci
difficulti
administr
increas
treatment
failur
due
develop
parasit
resist
last
coupl
decad
new
drug
develop
treatment
earlystag
hat
one
drug
develop
latestag
hat
need
great
new
oral
activ
drug
control
erad
diseas
novel
medicin
typic
develop
use
trialanderror
approach
timeconsum
costli
yet
potenti
yield
new
drug
applic
computerassist
drug
design
cadd
methodolog
problem
potenti
greatli
decreas
time
effort
requir
discov
new
medicin
improv
current
one
term
efficaci
review
focus
synthet
computerassist
drug
design
cadd
approach
made
variou
research
group
develop
newer
antitrypanosom
agent
improv
efficaci
oral
bioavail
current
research
also
endeavor
investig
relationship
variou
physiochem
paramet
antitrypanosom
activ
may
help
develop
potent
antitrypanosom
agent
sleep
sick
larg
number
structur
relat
congen
pentamidin
synthes
tidwel
rr
et
al
introduc
substitut
cation
group
chang
posit
dicat
posit
chang
length
aliphat
chain
two
aromat
ring
ad
substitu
aromat
ring
posit
replac
oxygen
atom
alkyl
linker
isoster
sulfur
nitrogen
atom
figur
compar
activ
synthes
compound
pentamidin
melarsoprol
found
compound
show
activ
rang
better
pentamidin
andor
melarsoprol
unsubstitut
diamidin
compound
figur
secondari
amino
group
place
oxygen
atom
exhibit
subnanomolar
activ
b
rhodesiens
nearli
twice
select
pathogen
pentamidin
time
diimidazolin
compound
figur
exhibit
second
highest
antitrypanosom
activ
seri
valu
also
highest
parasit
select
sit
time
select
b
rhodesiens
pentamidin
replac
oxygen
atom
sulphur
atom
compound
figur
also
gener
activ
congen
valu
better
pentamidin
compound
figur
cation
group
present
aromat
ring
length
carbon
linker
vari
exhibit
lower
antitrypanosom
activ
compar
pentamidin
wherea
among
compound
figur
seri
amidin
group
present
posit
length
aliphat
chain
vari
three
carbon
atom
six
carbon
atom
compound
figur
three
methylen
linker
aromat
ring
vitro
activ
pentamidin
introduct
substitu
compound
improv
antitrypanosom
properti
evid
vitro
activ
compound
figur
compound
excel
vitro
activ
evalu
vivo
mous
model
african
trypanosomiasi
screen
conduct
use
intraperiton
dose
mgkg
daili
four
day
compound
show
poor
vivo
activ
wherea
compound
exhibit
excel
vivo
efficaci
acut
mous
model
trypanosomiasi
provid
cure
infect
anim
thu
high
select
excel
vitro
vivo
activ
compound
serv
novel
lead
preclin
clinic
trial
cytotoxc
profil
need
monitor
evalu
also
compound
show
excel
vitro
vivo
activ
high
select
index
b
rhodesiens
merit
sar
optim
order
synthes
newer
lead
compound
reduc
cytotox
compar
pentamidin
increas
efficaci
pyridyl
analogu
furan
furamidin
encourag
tidwel
rr
et
al
synthes
pentamidin
analogu
phenyl
ring
pentamidin
replac
pyridyl
fragment
replac
result
seri
compound
figur
lower
cytotox
pentamidin
sar
studi
point
antiprotozo
properti
compound
depend
placement
cation
moieti
pyridin
ring
well
natur
substitu
amidin
group
nsubstitut
congen
lesser
cytotox
unsubstitut
diamidin
wherea
nalkyl
cation
fragment
reduc
activ
compound
brucei
rhodesiens
compar
pentamidin
trend
observ
pentamidin
analogu
seri
dicat
compound
figur
dicat
compound
figur
display
lower
potenc
brucei
rhodesiens
correspond
isom
compound
figur
among
dicat
compound
possess
cation
substitu
adjac
nitrogen
atom
pyridin
ring
display
superior
activ
parasit
compar
pentamidin
evid
compound
figur
show
promis
antitrypanosom
activ
lower
cytotox
pentamidin
melarsoprol
poor
vivo
activ
give
cure
mous
model
howev
diamidoxim
compound
figur
oral
prodrug
diamidin
compound
figur
exhibit
excel
vivo
activ
cure
four
four
anim
upon
oral
administr
mous
model
although
compound
provid
cure
cn
mous
model
infect
bbb
permeabl
could
potenti
improv
develop
prodrug
use
lipophil
substitut
place
hydrophil
substitut
use
compound
could
provid
higher
concentr
compound
cn
thu
excel
vitro
activ
diamidin
high
vivo
efficaci
prodrug
diamidoxim
warrant
investig
dicat
potenti
antitrypanosom
drug
candid
improv
oral
efficaci
structur
activ
relationship
two
seri
indic
case
unsubstitut
diamidin
activ
nsubstitut
diamidin
replac
oxygen
atom
alkyl
chain
secondari
amino
group
improv
activ
b
rhodesiens
pentamidin
analogu
case
pyridyl
analogu
compound
oxygen
atom
alkyl
chain
activ
one
potent
compound
two
seri
compound
figur
compound
figur
excel
vitro
activ
better
pentamidin
melarsoprol
also
high
select
b
rhodesiens
parasit
evid
select
index
si
compound
compound
initi
believ
oxygen
atom
aliphat
linker
amidin
group
import
antitrypanosom
activ
pentamidin
group
part
recognit
motif
amino
purin
transport
trypanosoma
speci
thu
activ
compound
explain
basi
case
compound
amidin
group
replac
imidazolin
oxygen
atom
replac
secondari
amino
group
despit
replac
compound
shown
excel
vitro
vivo
activ
thu
accord
recent
report
work
accord
direct
connect
affin
carrier
antitrypanosom
activ
view
two
compound
serv
lead
structur
develop
newer
analogu
pentamidin
reduc
side
effect
improv
pharmacokinet
profil
earli
dann
et
al
report
antitrypanosom
properti
two
bisbenzofuran
diaction
figur
two
phenylbenzofuran
figur
sinc
compound
receiv
littl
attent
howev
recent
lead
optim
studi
dicat
carri
tidwel
rr
et
al
synthes
report
vitro
vivo
activ
cytototix
dication
bisbenzofuran
deriv
figur
heterocycl
pentamidin
analogu
phenoxi
fragment
includ
benzofuran
structur
motif
tidwel
rr
et
al
also
synthes
seri
diaction
deriv
figur
tidwel
rr
et
al
found
vitro
antitrypanosom
activ
bisbenzofuran
deriv
trypanosoma
brucei
rhodesiens
cytotox
mammalian
cell
depend
posit
type
cation
substitu
well
length
carbon
linker
aromat
moieti
observ
dication
molecul
nsubstitut
congen
lesser
cytotox
unsubstitut
diamidin
wherea
nalkyl
cation
fragment
reduc
activ
compound
brucei
rhodesiens
compar
pentamidin
time
bisbenzofuran
gener
less
cytotox
compound
bear
substitu
bisbenzofuran
significantli
less
activ
b
rhodesiens
correspond
isom
vitro
activ
bisbenzofuran
seri
promis
lead
compound
figur
exhibit
vitro
antitrypanosom
activ
compar
pentamidin
melarsoprol
howev
compound
tidwel
seri
figur
show
reduc
cytotox
profil
compar
pentamidin
exampl
compound
cytotox
poor
select
profil
thu
prove
select
bisbenzofuran
b
rhodesiens
decreas
number
methylen
group
alkyl
bridg
increas
howev
substitut
amidin
group
affect
antitrypanosom
properti
bisbenzofuran
explain
thu
light
reduc
cytotox
compar
pentamidin
molecul
requir
investig
studi
influenc
type
cation
substitu
distanc
aromat
moieti
uptak
intracellular
distribut
dication
bisbenzofuran
order
understand
better
mode
action
thu
improv
efficaci
aromat
diamidin
tidwel
rr
et
al
synthes
evalu
activ
dication
deriv
figur
trypanosoma
brucei
rhodesiens
six
compound
figur
among
seri
includ
lead
compound
figur
exhibit
excel
vitro
vivo
antitrypanosom
activ
highli
select
b
rhodesiens
parasit
six
activ
compound
contain
diamidin
group
clearli
suggest
diamidin
exhibit
higher
antitrypanosom
activ
compar
di
nisopropyl
amidin
diimidazolin
substitut
dication
compound
figur
figur
show
better
antitrypanosom
activ
dication
compound
figur
wherea
among
substitut
diamidin
substitut
diamidin
select
parasit
dicat
higher
congen
introduct
hydroxi
substitu
compound
figur
result
compound
figur
compound
figur
enhanc
antitrypanosom
activ
higher
select
b
rhodesiens
dication
compound
evalu
anim
model
african
trypanosomiasisn
compound
show
exclel
vivo
activ
provid
cure
respect
administ
intraperiton
thu
promis
vitro
antitrypanosom
activ
excel
potenc
acut
mous
model
trypanosomiasi
reduc
cytotox
compound
compar
pentamidin
warrant
preclin
clinic
trial
molecul
compound
serv
lead
compound
sar
optim
deriv
congen
enhanc
activ
lesser
cytotox
combin
rigid
flexibl
pentamidin
congen
tidwel
rr
et
al
incorpor
benzofuran
ring
molecul
pentamidinerel
analogu
seri
pentamidin
congen
contain
benzofuran
fragment
figur
b
synthes
test
vitro
b
rhodesiens
compound
seri
show
cytotox
less
pentamidin
lesser
potenc
select
index
compar
pentamidin
properti
cytotox
dicat
depend
natur
cation
substitu
placement
benzofuran
motif
length
carbon
linker
within
seri
cytotox
compound
decreas
substitut
cation
group
increas
elong
carbon
linker
dicat
benzofuran
motif
compound
figur
connect
propylen
linker
potent
select
b
rhodesiens
among
seri
thu
basi
sar
studi
improv
made
order
produc
newer
antitrypanosom
agent
improv
pharmacolog
activ
sar
three
seri
clearli
indic
natur
cation
substitu
posit
import
decid
antitrypanosom
activ
benzofuran
deriv
introduct
phenoxi
fragment
benzofuran
structur
motif
may
result
retent
affin
aminopurin
transport
could
reason
antitrypanospom
activ
benzofuran
deriv
howev
precis
mechan
compound
show
antitrypanosom
activ
known
among
three
seri
deriv
attract
molecul
high
activ
low
cytotox
high
select
hat
parasit
introduct
phenoxi
fragment
aromat
ring
protect
phenylbenzofuran
derv
metabol
deactiv
structur
modif
retain
affin
aminopurin
transport
diamidin
hydroxi
methoxi
group
may
involv
bind
dna
minor
groov
thu
multipl
mode
action
may
reason
promis
antitrypanosom
propertri
deriv
thu
compound
requir
assess
order
develop
newer
antitrypanosom
agent
promis
pharmacokinet
profil
sinc
prodrug
furamidin
nmethoxi
amidinophenyl
furan
pafuramidin
shown
promis
result
clinic
trial
hat
therefor
furamidin
figur
gain
attent
evalu
produc
newer
antitrypanosom
analog
two
analogu
furamidin
figur
c
evalu
b
rhodesiens
mous
model
shown
promis
result
one
approach
enhanc
activ
furamidin
replac
central
furan
ring
heterocycl
system
includ
thiophen
pyrrol
oxazol
oxadiazol
thiadiazol
pyridazin
methylpyrimidin
triazin
structur
modif
past
result
compound
good
antiparasit
activ
exampl
boykin
dw
da
pb
report
synthesi
antiprotozo
activ
eighteen
substitut
furan
relat
analogu
includ
mask
amidin
guanyl
function
incorpor
heterocycl
ring
among
six
compound
produc
cure
mice
submilligram
dosag
level
somewhat
activ
screen
stilbamidin
hydroxystilbamidin
pentamidin
boykin
dw
et
al
report
synthesi
dication
diaryltriazin
nucleic
acid
bind
agent
year
boykin
dw
et
al
also
report
antipneumocysti
carinii
pneumonia
activ
dication
diaryl
methylprimidin
dann
et
al
year
report
isoxazol
figur
structur
similar
furamidin
report
high
activ
murin
brucei
rhodesiens
modelc
howev
compound
receiv
littl
attent
sinc
recent
optim
compound
report
result
sever
lead
compound
synthes
list
compound
tidwel
rr
et
al
recent
synthes
seri
analogu
figur
central
ring
furamidin
replac
isoxazol
activ
furamidin
melarsoprol
compar
among
synthes
dicat
compound
least
one
pamidin
moieti
compound
figur
compound
figur
display
good
valu
nm
nm
respect
compar
furamidin
nm
loss
potenc
observ
compound
substitut
diamidin
mposit
compound
nm
figur
gener
introduct
nitro
chloro
methoxi
substitu
either
aromat
ring
result
decreas
antitrypanosom
activ
howev
introduct
methoxi
group
aromat
ring
compound
result
compound
figur
compar
antitrypanosom
activ
nm
furamidin
henc
compound
isoxazol
seri
show
good
vitro
antitrypanosom
activ
less
cytotoxc
profil
rel
furamidin
could
candid
evalu
anim
model
diseas
howev
vivo
evalu
present
seri
report
yet
excel
antitrypanosom
activ
select
cation
diphenylisoxazol
provid
basi
synthesi
seri
cation
figur
tidwel
rr
et
al
fragment
use
suitabl
isoster
replac
central
fivememb
ring
furamidin
also
show
geometr
resembl
furamidin
observ
cytotox
triazol
lower
compar
pentamidin
affect
alkyl
amidin
group
substitut
aromat
ring
howev
placement
cation
moieti
increas
cytotox
diamidin
figur
respect
pentamidin
except
major
unsubstitut
diamidin
exhibit
higher
vitro
activ
brucei
rhodesiens
bi
nisopropyl
amidin
diimidazolin
compound
cation
fragment
compound
figur
aromat
ring
case
less
potent
brucei
rhodesiens
isom
bear
least
one
cation
moieti
compound
figur
howev
compound
figur
dication
moieti
posit
show
excel
vitro
activ
introduct
hydroxi
group
phenyl
ring
significantli
reduc
activ
increas
cytotoxc
brucei
rhodesiens
format
intramolecular
hydrogen
bond
hydrogen
atom
group
triazol
ring
vivo
analysi
compound
show
administ
mgkg
mgkg
mgkg
intraperiton
rout
cure
infect
anim
acut
mous
model
african
trypanosomiasi
thu
promis
vitro
vivo
antitrypanosom
activ
cation
deriv
particular
compound
necessit
investig
class
compound
potenti
antitrypanosom
drug
candid
replac
central
furan
ring
furamidin
either
isoxazol
result
compound
better
activ
furamidin
posit
natur
cation
substitu
govern
antitrypanosom
activ
two
seri
gener
para
substitut
diamidin
seri
promis
compound
good
activ
thu
compound
evalu
produc
better
analogu
furamidin
recent
report
n
nbi
piperazin
figur
shown
effect
vivo
antitrypanosom
agent
attract
interest
compound
henc
search
new
hat
chemotherapi
dardonvil
c
et
al
decid
carri
vitro
screen
total
compound
parasit
brucei
rhodesiens
taken
inhous
librari
base
show
bisguanidin
especi
bi
diphenyl
compound
display
potent
antitrypanosom
activ
vitro
vivo
b
rhodesiens
caus
agent
acut
hat
among
compound
screen
figur
show
excel
vitro
activ
nm
nm
nm
respect
well
high
select
respect
parasit
studi
reveal
compound
bear
cation
higher
select
parasit
similar
activ
respect
guanidin
counterpart
addit
correl
antitrypanosom
activ
dna
bind
affin
observ
suggest
possibl
mechan
action
compound
molecul
show
excel
vitro
activ
well
high
select
parasit
repres
new
antitrypanosom
lead
compound
light
promis
result
bi
deriv
deserv
investig
antitrypanosom
agent
dna
minor
groov
binder
synthesi
studi
new
deriv
prodrug
lead
compound
ongo
enzym
trypanothion
reductas
tr
restor
oxid
trypanothion
reduc
state
evolv
effect
drug
target
mani
inhibitor
enzym
develop
combat
problem
relat
bioavail
pharmacokinet
metabol
despit
quinolin
evolv
import
class
compound
tr
due
broad
spectrum
activ
excel
pharmacolog
pharmacokinet
properti
high
plasma
level
high
clearanc
oral
parenter
applic
chemic
stabil
rare
side
effect
view
gilbert
ih
report
screen
compound
librari
brucei
high
put
screen
ht
result
identif
two
novel
compound
seri
activ
enzym
trypanothion
reductas
seri
base
quinolin
scaffold
figur
compound
figur
methylfuran
group
posit
br
posit
quinolin
ring
nmethylethanamin
group
posit
potent
signific
tr
inhibitor
tr
inhibitori
activ
accord
sar
studi
replac
methylfuran
group
like
furan
phenyl
pyridinyl
thiophen
led
decreas
activ
also
replac
br
h
f
reduc
activ
cl
group
retain
activ
posit
nh
nme
group
equal
activ
alkylamin
activ
wherea
simpl
alkyl
aryl
group
led
inact
compound
second
seri
base
pyrimidopyridazin
scaffold
figur
compound
figur
show
promis
inhibitori
activ
case
seri
replac
methyl
group
posit
h
led
decreas
activ
posit
methyl
ethyl
group
show
activ
h
chain
extens
propyl
butyl
cyclopentan
led
decreas
activ
substitut
phenyl
alkenylphenyl
group
posit
gave
activ
compound
seri
thu
quinolin
compound
promis
activ
could
serv
lead
compound
develop
target
drug
african
trypanosomiasi
addit
synthet
optim
studi
base
lead
antitrypanosom
compound
figur
undertaken
werbovetz
ka
et
al
attempt
discov
new
trypanocid
potent
vivo
activ
target
tr
enzym
cours
total
compound
evalu
vitro
antitrypanosom
activ
cytotox
compound
oxygen
atom
posit
activ
compound
seri
exampl
compound
figur
show
better
antitrypanosom
activ
low
cytotox
melarsoprol
cytotox
wherea
compound
lack
atom
bear
oxygen
atom
rather
posit
far
less
potent
contain
alcohol
acyloxi
group
compound
carri
aliphat
ester
side
chain
potent
select
benzoyl
acetyl
counterpart
howev
compound
unstabl
due
autooxid
unstabl
alcohol
esterifi
gener
prodrug
figur
promis
activ
parasit
select
index
vivo
evalu
compound
murin
model
african
trypanosomiasi
show
good
result
prodrug
extend
lifespan
mice
infect
b
brucei
thu
compound
serv
lead
compound
investig
class
molecul
potenti
candid
hat
effort
also
undertaken
elucid
metabol
pharmacokinet
antitrypanosom
mechan
action
novel
promis
class
compound
dna
topoisomeras
evolv
effect
drug
target
prokaryot
eukaryot
system
enzym
mediat
mechanist
interact
supercoil
relax
knot
caten
dna
doubl
helic
base
mechan
action
topoisomeras
classifi
type
enzym
break
singl
strand
dna
helix
catalyt
cycl
type
ii
enzym
make
doublestrand
break
basi
primari
sequenc
reaction
mechan
type
topoisomeras
subdivid
type
ia
type
ib
recent
shapiro
ta
et
al
evalu
activ
indenoisoquinolin
figur
origin
known
anticanc
activ
brucei
found
compound
show
vitro
activ
submicromolar
concentr
compound
figur
propylamino
group
posit
methoxi
group
activ
one
vitro
antitrypanosom
activ
compound
also
show
good
vivo
activ
delay
parasitemia
extend
surviv
infect
mice
accord
structureact
analysi
compound
enhanc
potenc
includ
alkylamino
substitut
methoxi
group
methylenedioxi
bridg
test
indenoisoquinolin
promis
activ
mous
leukemia
cell
reveal
compound
effect
trypanosom
mammalian
cell
indenoisoquinolin
also
show
appreci
water
solubl
indic
compound
good
qualiti
drug
develop
compound
show
antitrypanosom
action
multipl
mechan
studi
indic
stabil
topoisomerasedna
complex
situ
may
also
imped
topoisomeras
bind
dna
agent
markedli
inhibit
dna
synthesi
interf
topoisomeras
possibl
dnametabol
enzym
thu
multipl
mechan
action
compound
trypanosom
attract
featur
sinc
compound
less
prone
drug
resist
therefor
indenoisoquinolin
compound
promis
lead
develop
drug
sleep
sick
addit
burri
c
et
al
test
fluroquinolon
deriv
specif
inhibitor
topoisomeras
cultur
bloodstream
form
b
rhodesiens
modif
quinolon
core
nucleu
figur
led
characterist
vitro
activ
toxic
metal
quinolon
ul
figur
f
group
posit
piperazin
posit
potent
compound
valu
ngml
dw
figur
thiazolopyrazin
incorpor
tetracycl
quinolin
kanebo
kanebo
figur
two
sulphanyl
fluoroquinolon
n
figur
also
activ
concentr
rang
ngml
ngml
dupont
compound
develop
antitumour
drug
highli
activ
also
show
high
cytotox
cell
observ
posit
posit
quinolon
core
nucleu
prerequisit
antitrypanosom
activ
also
substitut
posit
necessari
trypanocid
activ
thu
base
result
obtain
sar
analysi
special
attent
given
posit
tetracycl
deriv
vivo
result
compound
poor
none
compound
evalu
produc
cure
mice
dose
escal
experi
ip
howev
sign
toxic
observ
experi
vivo
ineffect
explain
drug
level
determin
plasma
treat
mice
perform
despit
failur
class
compound
attract
search
trypanocid
compound
complet
lack
toxic
sign
dosag
level
test
vivo
polyamin
gener
involv
growth
differenti
within
cell
analog
also
use
anticanc
agent
antiparasit
agent
antidiarrho
antihiv
agent
metal
chelat
gene
deliveri
agent
sinc
inhibit
initi
polyamin
biosynthesi
enzym
ornithin
decarboxylas
dfmo
toxic
african
trypanosom
cell
polyamin
becom
promis
antitrypanosom
compound
dfmo
recent
develop
agent
late
stage
b
gambiens
b
brucei
sleep
sick
activ
strain
b
rhodesiens
major
drawback
dfmo
cost
durat
treatment
avail
recent
clinic
studi
investig
dmfo
use
combin
clinic
use
trypanocid
includ
suramin
nifurtimox
melarsoprol
combin
result
signific
reduct
dfmo
dosag
time
administr
initi
clinic
studi
shown
dfmo
nifurtimox
superior
dfmo
melarsoprol
melarsoprol
nifurtimox
dfmo
nifurtimox
regimen
nect
regimen
allow
reduct
dfmo
regimen
day
versu
infus
cure
rate
associ
significantli
reduc
advers
side
effect
compar
melarsoprolbas
therapi
success
combin
regimen
like
due
abil
dmfo
reduc
trypanothion
level
resist
oxid
stress
abil
nifurtimox
gener
oxid
stress
addit
dfmo
number
agent
target
polyamin
metabol
shown
promis
includ
mdl
methyl
amino
enzymeactiv
inhibitor
sadenosylmethionin
adomet
decarboxylas
suppli
decarboxyl
adomet
sourc
aminopropyl
group
spermidin
spermin
synthesi
recent
gilbert
et
al
design
synthes
evalu
substitut
polyamin
carri
unit
potenti
antitrypanosom
drug
preliminari
result
indic
rout
might
success
lead
structur
figur
use
start
point
synthesi
two
seri
analogu
first
seri
influenc
structur
chang
central
core
unit
investig
second
seri
effect
addit
methyl
substitu
studi
compound
design
intent
select
target
interior
brucei
via
aminopurin
transport
first
seri
compound
contain
ndodecyl
chain
core
unit
show
weak
activ
b
rhodesiens
compound
nnonyl
chain
promis
compound
variou
analogu
design
replac
group
triazin
ring
nhme
group
introduct
one
two
methyl
group
per
triazin
unit
result
increas
antitrypanosom
activ
four
methyl
group
per
triazin
unit
introduc
increas
activ
observ
similarli
replac
group
ndodecyl
chain
led
higher
antitrypanosom
activ
methyl
deriv
monosubstitut
compound
show
slight
increas
activ
b
rhodesiens
compar
disubstitut
compound
methylamino
substitut
triazin
attach
compound
figur
compound
figur
polyamin
precursor
via
addit
linker
result
activ
trypanocid
compound
besid
good
activ
compound
show
poor
vivo
activ
produc
cure
infect
mice
concentr
greater
mg
induc
sever
acut
toxic
actual
mode
action
report
triazin
substitut
polyamin
remain
unclear
understand
improv
activ
compound
research
verifi
intracellular
drug
target
possibl
metabol
pathway
stanislaw
fw
et
al
report
antitrypanosom
activ
e
iodomethylen
adenosin
known
inhibitor
adohci
hydrolas
synthesi
inhibit
brucei
seri
analogu
modifi
includ
halomethylen
acetylen
oxim
deriv
e
iodomethylen
adenosin
eiddha
cyclopropyl
analogu
figur
b
shown
promis
vitro
inhibitori
activ
brucei
util
adenosin
analogu
antiparasit
explor
therapeut
paradigm
shown
previous
inhibitor
adohci
hydrolas
also
potent
inhibitor
growth
plasmodium
falciparum
class
adenosin
analogu
modifi
carbon
exhibit
inhibitori
effect
human
parasit
form
enzym
display
margin
antivir
activ
comparison
analogu
unmodifi
posit
potent
inhibitor
adohci
hydrolas
therefor
compound
requir
structur
modif
order
develop
newer
analogu
improv
activ
brucei
synthesi
morpholin
deriv
perozzo
r
et
al
result
discoveri
newer
class
antitrypanosom
compound
stage
specif
action
compound
shown
moder
good
activ
blood
stage
b
rhodesiens
two
compound
morpholin
figur
piperazin
figur
pyrazol
ring
potent
antitrypanosom
seri
cytotox
indic
pyrazol
ring
import
antitrypanosom
activ
substitut
pyrazol
ring
isoxazol
deriv
lead
six
fold
reduct
activ
compar
potent
compound
addit
substitut
nitrophenyl
aminophenyl
also
result
strong
reduct
activ
phenoxi
ring
compound
also
import
activ
replac
ethylen
group
result
nine
fold
reduct
efficaci
substitut
nitro
group
amino
group
reduc
potenc
respect
stage
specif
action
compound
unknown
optim
class
compound
requir
order
lower
cytotox
profil
compound
vitro
evalu
seri
n
coohblock
glutathion
deriv
carri
dsilva
daun
bloodstream
form
trypanosoma
brucei
trypomastigot
identifi
determin
necessari
activ
develop
activ
lead
structur
result
show
n
sblock
glutathion
diester
activ
inhibitor
brucei
parasit
nacetylsbenzyloxycarbonylglutathion
dimethyl
ester
compound
n
diester
deriv
compound
figur
repres
lead
structur
possess
minim
toxic
potenti
could
develop
yield
therapeut
activ
agent
treatment
trypanosomiasi
boykin
dw
et
al
syhthes
evalu
five
oalkoxyamidin
analogu
prodrug
furan
trypanosoma
brucei
rhodesiens
mous
model
oral
administr
observ
size
oalkyl
sidechain
determin
metabol
stabil
prodrug
prodrug
omethyl
analogu
suscept
metabol
larger
onbutyl
onhexyl
group
least
suscept
metabol
vivo
studi
mous
model
b
rhodesiens
show
compound
omethoxyamidin
oethoxyamidin
group
effect
cure
trypanosomeinfect
mice
wherea
prodrug
larger
sidechain
complet
cure
mice
therefor
oalkoxyamidin
prodrug
alkyl
chain
less
three
carbon
could
effect
use
prodrug
amidin
boykin
dw
et
al
also
prepar
azaanalogu
furamidin
exhibit
high
vitro
activ
b
rhodesiens
sever
prodrug
azaanalogu
figur
show
excel
oral
activ
vivo
superior
furamidin
methoxyamidino
phenyl
furan
nhydroxyamidinophenyl
furan
b
rhodesiens
mous
model
found
sever
excel
candid
evalu
b
rhodesiens
addit
mention
prodrug
synthesi
boykin
dw
et
al
also
report
bisamidoxim
bisoalkylamidoxim
number
diamidin
system
effect
prodrug
order
develop
oral
effect
antitrypanosom
agent
synthes
two
type
potenti
prodrug
terphenyl
seri
found
compound
figur
show
good
activ
rang
nm
among
compound
lower
cytotox
profil
poor
vivo
activ
cure
none
infect
anim
mous
model
wherea
compound
show
excel
vivo
activ
cure
infect
anim
upon
oral
administr
mous
model
capit
efficaci
potent
dicat
prodrug
reli
differ
bioconvers
pathway
need
develop
boykin
dw
et
al
show
dication
guanidin
nalkylguanidin
revers
amidin
deriv
fuse
ring
system
good
vitro
activ
trypanosoma
brucei
rhodesiens
dication
figur
show
promis
vivo
biolog
result
give
cure
treat
anim
anim
model
african
trypanosomiasi
addit
nmethyl
analogu
figur
also
show
high
activ
give
cure
treat
anim
anim
model
african
trypanosomiasi
order
enhanc
oral
bioavail
two
novel
class
potenti
guanidin
prodrug
prepar
nalkoxyguanidin
deriv
figur
effect
prodrug
wherea
carbam
prodrug
figur
gave
promis
result
cure
oral
administr
mous
model
result
show
compound
bind
strongli
dna
minor
groov
despit
strong
bond
compound
high
antiparasit
activ
compar
last
year
reviv
drug
research
develop
regard
neglect
parasit
diseas
number
drug
develop
project
current
ongo
howev
discov
lead
compound
antitrypanosom
activ
remain
crucial
step
sustain
progress
achiev
till
date
use
computerassist
drug
design
cadd
sinc
start
becom
increasingli
help
understand
mani
aspect
chemicalbiolog
interact
drug
scientif
research
latest
technolog
advanc
qsar
structurebas
design
ligandbas
design
cheminformat
bioinformat
provid
much
improv
basi
design
ligand
inhibitor
desir
specif
recent
computerassist
drug
design
approach
base
ligandbas
structur
base
drug
design
success
employ
develop
new
drug
treatment
cancer
aid
diseas
qsar
wide
use
year
provid
quantit
analysi
structur
activ
relationship
compound
statist
method
appli
qsar
model
establish
correl
chemic
structur
biolog
activ
valid
find
use
predict
activ
untest
compound
though
countabl
sustain
attempt
made
build
molecular
model
field
hat
exemplifi
work
prashanth
et
al
perform
qsar
analysi
librari
heterocycl
diamidin
deriv
antiparasit
activ
martin
mb
et
perform
comfa
analysi
bisphosphon
trypanosoma
brucei
rhodesiens
prashanth
et
al
perform
comfa
comsia
base
qsar
analysi
furamidin
set
structur
relat
compound
main
goal
studi
correl
structur
featur
class
compound
biolog
activ
use
knowledg
dna
minor
groov
bioreceptor
sequenc
two
differ
align
strategi
base
put
kinetoplast
dna
minor
groov
target
use
due
conserv
electrostat
properti
across
compound
model
use
steric
electron
properti
perform
well
predict
biolog
result
extend
comsia
model
addit
descriptor
hydrophob
donor
acceptor
properti
good
predict
abil
see
standard
error
estim
f
result
use
guid
design
compound
potenti
better
activ
african
trypanosom
specif
deriv
chemic
properti
import
activ
view
develop
model
adopt
ration
approach
toward
select
substitu
variou
posit
scaffold
inform
use
predict
new
compound
synthesi
high
probabl
enhanc
activ
martin
mb
et
first
provid
evid
enzym
farnesyl
pyrophosph
synthas
princip
site
action
bisphosphon
risedron
inhibit
growth
bloodstreamform
b
rhodesiens
trypomastigot
caus
agent
human
east
african
trypanosomiasi
also
report
analysi
bisphosphon
yield
theoreticalversusexperiment
correl
crossvalid
valu
first
report
qsarcomfa
correl
act
antiparasit
agent
result
use
design
develop
bisphosphon
antiparasit
agent
daun
dsilva
perform
qsar
analysi
order
deriv
contribut
log
p
es
vitro
antiprotozo
activ
glutathion
deriv
analysi
inhibit
data
vs
calcul
log
p
es
valu
provid
evid
support
membran
penetr
steric
factor
key
compon
activ
compound
optimum
valu
log
p
es
determin
respect
best
linear
qsar
equat
deriv
process
elimin
use
set
compound
exclud
outlier
eq
f
log
logp
w
equat
indic
therapeut
activ
compound
decreas
increas
valu
log
p
es
core
research
group
also
perform
qsar
analysi
dication
diphenylisoxazol
studi
attempt
investig
relationship
variou
physiochem
paramet
antitrypanosom
activ
dication
may
help
develop
potent
antitrypanosom
agent
sleep
sick
sever
statist
express
develop
use
stepwis
multipl
linear
regress
analysi
mlr
partial
least
squar
pl
best
mlr
model
show
good
correl
predict
abil
shown
follow
equat
energi
p
lipol
f
compar
pl
model
also
obtain
develop
model
valid
leaveoneout
method
crossvalid
predict
test
set
studi
indic
antitrypanosom
activ
larg
explain
cosmic
energi
log
p
total
lipol
descriptor
qsar
studi
report
present
studi
provid
import
structur
insight
relat
antitrypanosom
activ
author
develop
valid
highli
predict
model
share
import
structur
requir
effect
bind
antitrypanosom
compound
minor
groov
b
rhodesiens
dna
model
report
studi
help
develop
new
compound
improv
efficaci
oral
bioavail
line
develop
model
author
also
design
molecul
show
good
activ
silico
studi
compound
progress
poor
pharmacokinet
profil
toxic
produc
drug
current
use
treat
trypanosomiasi
requir
immedi
attent
develop
safe
econom
high
affin
chemotherapeut
agent
meet
need
class
drug
unaccept
truth
lack
attent
govern
less
interest
pharmaceut
compani
light
less
monitori
gain
area
protozo
infect
sinc
affect
peopl
belong
poorer
countri
surprisingli
endeavor
differ
research
group
discuss
review
belong
academ
institut
felt
research
treatment
hat
requir
combin
approach
govern
organ
pharmaceut
compani
academ
institut
promis
fact
last
decad
sever
synthet
approach
made
field
develop
antitrypanosom
therapi
sever
compound
synthes
yield
new
compound
treatment
hat
result
synthet
approach
newer
lead
identifi
differ
phase
drug
develop
promis
vitro
vivo
activ
dication
molecul
clearli
indic
aromat
diamidin
promis
class
compound
develop
newer
drug
hat
import
one
newer
analog
exist
drug
pentamidin
compound
figur
figur
show
excel
vivo
vitro
activ
respect
also
good
select
index
parasit
cytotox
attempt
synthesis
newer
compound
reduc
cytotox
pentamidin
molecul
sever
benzofuran
deriv
synthes
howev
replac
phenoxi
fragement
pentamidin
benzofuran
motif
result
poor
analogu
lower
antitrypanosom
activ
improv
cytotox
profil
howev
strong
activ
b
rhodesiens
isol
indic
step
taken
initi
studi
compound
compound
evolv
new
lead
compound
newer
analogu
furamidin
also
show
promis
antitrypanosom
activ
along
lower
cytotox
furamidin
thu
strong
activ
b
rhodesiens
lower
cytotox
compound
figur
indic
compound
evalu
thu
dna
minor
grove
binder
still
interest
potenti
target
develop
newer
antitrypanosom
agent
apart
diamidin
polyamin
guanidin
also
potenti
give
antitrypanosom
compound
success
dmfo
polyamin
inhibitor
attract
research
synthesi
develop
agent
target
polyamin
metabol
recent
polyamin
carri
unit
synthes
evalu
brucei
compound
exhibit
good
activ
cytotox
morpholin
dihydroquinolin
also
shown
promis
vivo
antitrypanosom
activ
addit
develop
prodrug
exist
compound
also
promis
address
pharmacokinet
relat
problem
near
futur
thu
excel
vitro
vivo
activ
high
select
aforement
compound
merit
investig
order
reduc
cytotox
may
result
develop
newer
antitrypanosom
drug
reduc
toxic
improv
efficaci
pharmacokinet
profil
drug
discoveri
develop
process
expens
term
time
money
cross
applic
exist
seri
compound
select
trypanocid
activ
may
best
prospect
new
antitrypanosom
drug
short
term
emphasi
put
field
cadd
approach
develop
antitrypanosom
agent
cadd
studi
reduc
time
cost
requir
develop
newer
analogu
